$MRK Merck & Co. Inc. Company Overview
Merck & Co., Inc. discovers, develops and markets a broad range of human and animal health products. It is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company's products cover a broad range of areas, including heart and respiratory health, infectious diseases, sun care and women's health. It provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company operates its business through four operating segments: Pharmaceutical, Animal Health, Consumer Care and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the company or through joint ventures. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The company sells these products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Its vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The company sells these vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines, which it sells to veterinarians, distributors and animal producers. The Consumer Care segment develops, manufactures and markets over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets in the United States and Canada. The Alliances segment includes revenue from the company relationship with AstraZeneca LP. The company was founded in 1851 and is headquartered in Whitehouse Station, NJ.
MRK Last Price: 48.94
Last Updated: November 24, 2013 1:39 AM EST
MRK Stock Message Board and Forum http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
Merck & Co. Inc. MRK Officers and Executives
Name Age Officer Since Title
Mr. Kenneth C. Frazier 58 1992 Chairman, President & Chief Executive Officer
Mr. Peter N. Kellogg 57 2007 Chief Financial Officer & Executive Vice President
Mr. Clark Golestani - 2003 Chief Information Officer & Executive VP
Dr. Michael A. Rosenblatt 65 2009 Chief Medical Officer & Executive Vice President
Dr. Roger M. Perlmutter 60 1997 EVP-Worldwide Basic & Preclinical Research
Merck & Co., Inc.
One Merck Drive
Whitehouse Station, New Jersey 08889-3400
Phone
1 9084231000
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$47.35B
Net Income
$6.17B
Employees
83,000
Annual Report Below for MRK
Merck & Co. Inc. MRK Recent Headlines
MarketWatch News on MRK
Merck, J.P. Morgan lead Dow decliners 9:35 a.m. Nov. 13, 2013 - Laura Mandaro
Merck, Cisco lead gainers in Dow industrials 4:03 p.m. Nov. 12, 2013 - Polya Lesova
How to invest in and buy a bitcoin 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Planned layoffs up 13.5% in October: Challenger 7:30 a.m. Nov. 6, 2013 - Steve Goldstein
Newscast: S&P 500 notches year's 32nd record high 8:08 p.m. Oct. 28, 2013 - MarketWatch
J.C. Penney, Bristol-Myers top S&P 500 7:08 p.m. Oct. 28, 2013 - Saumya Vaishampayan
S&P up for 8th day in 9; Dow, Nasdaq flat 4:57 p.m. Oct. 28, 2013 - Victor Reklaitis
Newscast: Stocks mixed after lackluster day 4:26 p.m. Oct. 28, 2013 - MarketWatch
Newscast: Car reliability ranks get new members 2:28 p.m. Oct. 28, 2013 - MarketWatch
Merck shares stumble on earnings weakness, talk of divesting assets 10:58 a.m. Oct. 28, 2013 - blogs.marketwatch.com
Merck, down 2.2%, leads Dow average lower 9:34 a.m. Oct. 28, 2013 - Laura Mandaro
Stock futures continue to waver after data 9:30 a.m. Oct. 28, 2013 - Sara Sjolin
Apple is Monday’s stock to watch as results loom 8:21 a.m. Oct. 28, 2013 - Sue Chang
Merck profit down 35% as Singulair sales fall 7:25 a.m. Oct. 28, 2013 - MarketWatch.com
Merck third-quarter profit, revenue fall 7:17 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck narrows 2013 EPS guidance; holds sales view 7:10 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 adj. EPS edges down to $0.92 vs. $0.95 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 sales down to $11.03 bln vs. $11.49 bln 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 profit falls to $1.12 bln vs. $1.73 bln 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 EPS falls to $0.38 from $0.56 year ago 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Recent Cloud IPO Veeva Systems Scores In Health Biz 3:31 p.m. Nov. 22, 2013 - Investors Business Daily
Watch For Today's Momo Momentum Stock: Merck (MRK) 12:05 p.m. Nov. 22, 2013 - TheStreet.com
Dow Today: Merck (MRK) Higher 12:00 p.m. Nov. 22, 2013 - TheStreet.com
Gilead Hepatitis C Drug Wins EU Panel Vote Early 10:28 a.m. Nov. 22, 2013 - Investors Business Daily
Merck & Co Inc (MRK): Today's Featured Drugs Winner 5:00 p.m. Nov. 21, 2013 - TheStreet.com
Stock Market News for November 21, 2013 - Market News 10:06 a.m. Nov. 21, 2013 - Zacks.com
Eight Big Dividend Hikes Expected Before 2013 Ends 6:56 a.m. Nov. 21, 2013 - 247WallSt.com
The Race For A Cure For Cancer 1:44 p.m. Nov. 20, 2013 - Seeking Alpha
Celgene Vs. Rivals In Psoriatic Arthritis Drug Race 4:16 a.m. Nov. 20, 2013 - Seeking Alpha
QIAGEN, Eli Lilly Expand Partnership - Analyst Blog 6:58 p.m. Nov. 19, 2013 - Zacks.com
New Tricks in Animal Health 6:05 p.m. Nov. 19, 2013 - WSJ.com
JPMorgan Exits China Everbright Bank Share Sale and 2 Other Dow Movers to Watch 1:24 p.m. Nov. 19, 2013 - Wall St. Cheat Sheet
European Approval for Gilead's Vitekta - Analyst Blog 11:40 a.m. Nov. 19, 2013 - Zacks.com
The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years 11:03 a.m. Nov. 19, 2013 - 247WallSt.com
Merck & Co Inc Continues With Buy Recommendation 9:00 a.m. Nov. 19, 2013 - TheStreet.com
Investments On Biotech's Cutting Edge: Joseph Pantginis 4:41 p.m. Nov. 18, 2013 - Seeking Alpha
Merck Scores in Investigational Melanoma Study Results 1:23 p.m. Nov. 18, 2013 - 247WallSt.com
Narrower-than-Expected Loss at Achillion, Shares Up - Analyst Blog 9:50 a.m. Nov. 18, 2013 - Zacks.com
10 Companies In The Spotlight This Week 3:33 a.m. Nov. 18, 2013 - Seeking Alpha
Paul Tudor Jones - High Impact Sells 1:12 p.m. Nov. 16, 2013 - GuruFocus.com
Press Releases on MRK
European Patent Office Issues Decision Regarding Universal Display's Organometallic Iridium Patent 9:01 a.m. Nov. 22, 2013 - BusinessWire
Sixth Annual Biotech Showcase(TM) Returns to San Francisco January 13-15 6:51 p.m. Nov. 21, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Merck Consumer Health Turnaround on Track 4:00 a.m. Nov. 21, 2013 - BusinessWire
Critical Alerts For Netflix, Salesforce.com, Goldman Sachs, Merck, and Valero Energy Released By InvestorsObserver 9:31 a.m. Nov. 19, 2013 - PR Newswire
Merck for Mothers Working to End the Tragedy of Women in America Dying in Childbirth and Pregnancy 8:30 a.m. Nov. 19, 2013 - PR Newswire
Additional Interim Data for Merck's Investigational Anti-PD-1 Immunotherapy, MK-3475, Shows Estimated Overall Survival Rate of 81 Percent at One Year in Patients with Advanced Melanoma 12:00 p.m. Nov. 18, 2013 - BusinessWire
Merck Partners With TRUSTe to Become Certified Under APEC Cross Border Privacy Rules 9:00 a.m. Nov. 18, 2013 - Marketwire
Merck's New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review 8:30 a.m. Nov. 18, 2013 - BusinessWire
RedHill Biopharma Announces Positive Scientific Advice Meeting and European Marketing Application Strategy for RHB-103 (Migraine) 8:00 a.m. Nov. 18, 2013 - GlobeNewswire
Interim Data to Be Presented for MK-3475, Merck's Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma 5:00 p.m. Nov. 15, 2013 - BusinessWire
Akorn Acquires Three Branded Ophthalmic Products from Merck 9:00 a.m. Nov. 15, 2013 - BusinessWire
Merck Strengthens its Presence in China with New Pharmaceutical Manufacturing Facility 2:00 a.m. Nov. 15, 2013 - PR Newswire
Today's Research: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 6:21 p.m. Nov. 14, 2013 - PR Newswire
Healthcare Sector Announces Financial Results and Financial Restatements - Research Report on Merck, Health Management Associates, ZELTIQ, MAKO, and Amarin 8:00 a.m. Nov. 13, 2013 - PR Newswire
Merck Enters into Further Global Co-Development and Commercialization Agreement for PARP Inhibitor with Chinese R&D Company BeiGene 2:30 a.m. Nov. 13, 2013 - PR Newswire
InSite Vision Reports Third Quarter 2013 Financial Results 4:03 p.m. Nov. 12, 2013 - BusinessWire
Merck Animal Health HomeAgain® Announces Hero of the Year Award Winner 8:00 a.m. Nov. 12, 2013 - PR Newswire
Acquisition, Corporate News Analysis: Apple Inc, Bank of America, Intel Corporation, Merck & Co, Globalstar 9:15 a.m. Nov. 11, 2013 - PR Newswire
Clinical Study Results, Approvals, Financial Results, New Facilities, and Business Expansions - Research Report on Merck, UnitedHealth Group, NPS Pharmaceuticals, Abbott, and Medtronic 8:00 a.m. Nov. 11, 2013 - PR Newswire
Valuation
P/E Current
24.47
P/E Ratio (with extraordinary items)
31.97
P/E Ratio (without extraordinary items)
20.47
Price to Sales Ratio
2.63
Price to Book Ratio
2.34
Price to Cash Flow Ratio
12.57
Enterprise Value to EBITDA
8.29
Enterprise Value to Sales
3.25
Total Debt to Enterprise Value
0.16
Efficiency
Revenue/Employee
0.57
Income Per Employee
0.07
Receivables Turnover
5.89
Total Asset Turnover
0.45
Liquidity
Current Ratio
1.90
Quick Ratio
1.54
Cash Ratio
0.90
Profitability
Gross Margin
65.66
Operating Margin
22.16
Pretax Margin
18.46
Net Margin
13.02
Return on Assets
5.84
Return on Equity
11.47
Return on Total Capital
8.47
Return on Invested Capital
8.85
Capital Structure
Total Debt to Total Equity
38.79
Total Debt to Total Capital
27.95
Total Debt to Total Assets
19.38
Long-Term Debt to Equity
30.66
Long-Term Debt to Total Capital
22.09
Merck & Co. Inc. MRK Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 23.85B 27.43B 45.91B 48.13B 47.35B
Cost of Goods Sold (COGS) incl. D&A 5.46B 9.02B 18.4B 16.41B 16.26B
COGS excluding D&A 3.83B 6.44B 11.02B 8.98B 9.28B
Depreciation & Amortization Expense 1.63B 2.58B 7.38B 7.43B 6.98B
Depreciation 1.45B 1.65B 2.68B 2.33B 1.98B
Amortization of Intangibles 186.1M 921.8M 4.7B 5.1B 5B
Gross Income 18.39B 18.41B 27.52B 31.73B 31.09B
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 11.95B 14.27B 24.13B 21.34B 20.6B
Research & Development 4.68B 5.85B 10.99B 7.88B 7.91B
Other SG&A 7.28B 8.43B 13.14B 13.46B 12.69B
Other Operating Expense 0 0 0 0 0
Unusual Expense (778.6M) 1.83B 1.12B 2.6B 2.13B
EBIT after Unusual Expense 778.6M (1.83B) (1.12B) (2.6B) (2.13B)
Non Operating Income/Expense (226.7M) 11B (566M) (519M) 221M
Non-Operating Interest Income 631.4M 210.2M 83M 199M 232M
Equity in Affiliates (Pretax) 2.56B 2.24B 587M 610M 642M
Interest Expense 251.3M 458M 715M 749M 714M
Gross Interest Expense 251.3M 458M 715M 749M 714M
Interest Capitalized 0 0 0 0 -
Pretax Income 9.93B 15.29B 1.65B 7.33B 8.74B
Income Tax 2B 2.27B 671M 942M 2.44B
Income Tax - Current Domestic 1.18B (48M) 317M 911M 1.12B
Income Tax - Current Foreign 292.4M 495.4M 1.45B 1.57B 651M
Income Tax - Deferred Domestic 474.3M 2.26B 685M (854M) 992M
Income Tax - Deferred Foreign 55.8M (437.3M) (1.78B) (683M) (323M)
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 - (15M) (3M)
Consolidated Net Income 7.93B 13.02B 982M 6.38B 6.3B
Minority Interest Expense 123.9M 122.9M 121M 120M 131M
Net Income 7.81B 12.9B 861M 6.26B 6.17B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 7.81B 12.9B 861M 6.26B 6.17B
Preferred Dividends 0 2.1M 0 0 0
Net Income Available to Common 7.81B 12.9B 861M 6.26B 6.17B
EPS (Basic) 3.66 5.67 0.28 2.04 2.03
Basic Shares Outstanding 2.14B 2.27B 3.1B 3.07B 3.04B
EPS (Diluted) 3.64 5.65 0.28 2.02 2.00
Diluted Shares Outstanding 2.15B 2.27B 3.12B 3.09B 3.08B
EBITDA 8.07B 6.71B 10.77B 17.82B 17.47B
Merck & Co. Inc. MRK Filings
SEC Filings for Merck & Co. Inc.
Filing Date Document Date Type Category Amended
11/07/2013 09/30/2013 10-Q Quarterly Reports
10/28/2013 10/28/2013 8-K Special Events
10/01/2013 09/30/2013 8-K Special Events
08/07/2013 06/30/2013 10-Q Quarterly Reports
07/30/2013 07/30/2013 8-K Special Events
05/30/2013 05/28/2013 8-K Special Events
05/22/2013 05/20/2013 8-K Special Events
05/20/2013 05/20/2013 8-K Special Events
05/09/2013 03/31/2013 10-Q Quarterly Reports
05/01/2013 05/01/2013 8-K Special Events
04/15/2013 05/28/2013 DEF 14A Proxy Statement
03/07/2013 03/04/2013 8-K Special Events
02/28/2013 12/31/2012 10-K Annual Reports
02/19/2013 02/14/2013 8-K Special Events
02/13/2013 N/A SC 13G/A Institutional Ownership *
02/05/2013 N/A SC 13G/A Institutional Ownership *
02/01/2013 02/01/2013 8-K Special Events
11/29/2012 11/26/2012 8-K Special Events
11/09/2012 09/30/2012 10-Q Quarterly Reports
10/26/2012 10/26/2012 8-K Special Events
SEC Filings provided by EDGAR Online, Inc.
MRK Merck & Co. Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/MRK/quote
Stock Chart http://www.otcmarkets.com/stock/MRK/chart
Company Info http://www.otcmarkets.com/stock/MRK/company-info
Recent News http://www.otcmarkets.com/stock/MRK/news
Financials http://www.otcmarkets.com/stock/MRK/financials
Filings and Disclosure http://www.otcmarkets.com/stock/MRK/filings
Short Sales http://www.otcmarkets.com/stock/MRK/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/MRK/insider-transactions
Research Reports http://www.otcmarkets.com/stock/MRK/research
Summary http://finance.yahoo.com/q?s=MRK
Historical Prices http://finance.yahoo.com/q/hp?s=MRK+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=MRK
Basic Chart http://finance.yahoo.com/q/bc?s=MRK+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=MRK+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=MRK+Headlines
Press Releases http://finance.yahoo.com/q/p?s=MRK+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=MRK+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=MRK+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=MRK+Industry
Major Holders http://finance.yahoo.com/q/mh?s=MRK+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=MRK+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=MRK+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=MRK
Balance Sheet http://finance.yahoo.com/q/bs?s=MRK
Cash Flow http://finance.yahoo.com/q/cf?s=MRK+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/MRK
Market Watch http://www.marketwatch.com/investing/stock/MRK
Bloomberg http://www.bloomberg.com/quote/MRK:US
Morningstar http://quotes.morningstar.com/stock/s?t=MRK
Bussinessweek http://investing.businessweek.com/research/st...ticker=MRK
Barchart http://www.barchart.com/quotes/stocks/MRK
OTC Short Report http://otcshortreport.com/index.php?index=MRK
Investopedia http://www.investopedia.com/markets/stocks/MRK/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
Merck & Co., Inc. discovers, develops and markets a broad range of human and animal health products. It is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company's products cover a broad range of areas, including heart and respiratory health, infectious diseases, sun care and women's health. It provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company operates its business through four operating segments: Pharmaceutical, Animal Health, Consumer Care and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the company or through joint ventures. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The company sells these products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Its vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The company sells these vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines, which it sells to veterinarians, distributors and animal producers. The Consumer Care segment develops, manufactures and markets over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets in the United States and Canada. The Alliances segment includes revenue from the company relationship with AstraZeneca LP. The company was founded in 1851 and is headquartered in Whitehouse Station, NJ.
MRK Last Price: 48.94
Last Updated: November 24, 2013 1:39 AM EST
MRK Stock Message Board and Forum http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
Merck & Co. Inc. MRK Officers and Executives
Name Age Officer Since Title
Mr. Kenneth C. Frazier 58 1992 Chairman, President & Chief Executive Officer
Mr. Peter N. Kellogg 57 2007 Chief Financial Officer & Executive Vice President
Mr. Clark Golestani - 2003 Chief Information Officer & Executive VP
Dr. Michael A. Rosenblatt 65 2009 Chief Medical Officer & Executive Vice President
Dr. Roger M. Perlmutter 60 1997 EVP-Worldwide Basic & Preclinical Research
Merck & Co., Inc.
One Merck Drive
Whitehouse Station, New Jersey 08889-3400
Phone
1 9084231000
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$47.35B
Net Income
$6.17B
Employees
83,000
Annual Report Below for MRK
Merck & Co. Inc. MRK Recent Headlines
MarketWatch News on MRK
Merck, J.P. Morgan lead Dow decliners 9:35 a.m. Nov. 13, 2013 - Laura Mandaro
Merck, Cisco lead gainers in Dow industrials 4:03 p.m. Nov. 12, 2013 - Polya Lesova
How to invest in and buy a bitcoin 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Planned layoffs up 13.5% in October: Challenger 7:30 a.m. Nov. 6, 2013 - Steve Goldstein
Newscast: S&P 500 notches year's 32nd record high 8:08 p.m. Oct. 28, 2013 - MarketWatch
J.C. Penney, Bristol-Myers top S&P 500 7:08 p.m. Oct. 28, 2013 - Saumya Vaishampayan
S&P up for 8th day in 9; Dow, Nasdaq flat 4:57 p.m. Oct. 28, 2013 - Victor Reklaitis
Newscast: Stocks mixed after lackluster day 4:26 p.m. Oct. 28, 2013 - MarketWatch
Newscast: Car reliability ranks get new members 2:28 p.m. Oct. 28, 2013 - MarketWatch
Merck shares stumble on earnings weakness, talk of divesting assets 10:58 a.m. Oct. 28, 2013 - blogs.marketwatch.com
Merck, down 2.2%, leads Dow average lower 9:34 a.m. Oct. 28, 2013 - Laura Mandaro
Stock futures continue to waver after data 9:30 a.m. Oct. 28, 2013 - Sara Sjolin
Apple is Monday’s stock to watch as results loom 8:21 a.m. Oct. 28, 2013 - Sue Chang
Merck profit down 35% as Singulair sales fall 7:25 a.m. Oct. 28, 2013 - MarketWatch.com
Merck third-quarter profit, revenue fall 7:17 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck narrows 2013 EPS guidance; holds sales view 7:10 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 adj. EPS edges down to $0.92 vs. $0.95 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 sales down to $11.03 bln vs. $11.49 bln 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 profit falls to $1.12 bln vs. $1.73 bln 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 EPS falls to $0.38 from $0.56 year ago 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Recent Cloud IPO Veeva Systems Scores In Health Biz 3:31 p.m. Nov. 22, 2013 - Investors Business Daily
Watch For Today's Momo Momentum Stock: Merck (MRK) 12:05 p.m. Nov. 22, 2013 - TheStreet.com
Dow Today: Merck (MRK) Higher 12:00 p.m. Nov. 22, 2013 - TheStreet.com
Gilead Hepatitis C Drug Wins EU Panel Vote Early 10:28 a.m. Nov. 22, 2013 - Investors Business Daily
Merck & Co Inc (MRK): Today's Featured Drugs Winner 5:00 p.m. Nov. 21, 2013 - TheStreet.com
Stock Market News for November 21, 2013 - Market News 10:06 a.m. Nov. 21, 2013 - Zacks.com
Eight Big Dividend Hikes Expected Before 2013 Ends 6:56 a.m. Nov. 21, 2013 - 247WallSt.com
The Race For A Cure For Cancer 1:44 p.m. Nov. 20, 2013 - Seeking Alpha
Celgene Vs. Rivals In Psoriatic Arthritis Drug Race 4:16 a.m. Nov. 20, 2013 - Seeking Alpha
QIAGEN, Eli Lilly Expand Partnership - Analyst Blog 6:58 p.m. Nov. 19, 2013 - Zacks.com
New Tricks in Animal Health 6:05 p.m. Nov. 19, 2013 - WSJ.com
JPMorgan Exits China Everbright Bank Share Sale and 2 Other Dow Movers to Watch 1:24 p.m. Nov. 19, 2013 - Wall St. Cheat Sheet
European Approval for Gilead's Vitekta - Analyst Blog 11:40 a.m. Nov. 19, 2013 - Zacks.com
The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years 11:03 a.m. Nov. 19, 2013 - 247WallSt.com
Merck & Co Inc Continues With Buy Recommendation 9:00 a.m. Nov. 19, 2013 - TheStreet.com
Investments On Biotech's Cutting Edge: Joseph Pantginis 4:41 p.m. Nov. 18, 2013 - Seeking Alpha
Merck Scores in Investigational Melanoma Study Results 1:23 p.m. Nov. 18, 2013 - 247WallSt.com
Narrower-than-Expected Loss at Achillion, Shares Up - Analyst Blog 9:50 a.m. Nov. 18, 2013 - Zacks.com
10 Companies In The Spotlight This Week 3:33 a.m. Nov. 18, 2013 - Seeking Alpha
Paul Tudor Jones - High Impact Sells 1:12 p.m. Nov. 16, 2013 - GuruFocus.com
Press Releases on MRK
European Patent Office Issues Decision Regarding Universal Display's Organometallic Iridium Patent 9:01 a.m. Nov. 22, 2013 - BusinessWire
Sixth Annual Biotech Showcase(TM) Returns to San Francisco January 13-15 6:51 p.m. Nov. 21, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Merck Consumer Health Turnaround on Track 4:00 a.m. Nov. 21, 2013 - BusinessWire
Critical Alerts For Netflix, Salesforce.com, Goldman Sachs, Merck, and Valero Energy Released By InvestorsObserver 9:31 a.m. Nov. 19, 2013 - PR Newswire
Merck for Mothers Working to End the Tragedy of Women in America Dying in Childbirth and Pregnancy 8:30 a.m. Nov. 19, 2013 - PR Newswire
Additional Interim Data for Merck's Investigational Anti-PD-1 Immunotherapy, MK-3475, Shows Estimated Overall Survival Rate of 81 Percent at One Year in Patients with Advanced Melanoma 12:00 p.m. Nov. 18, 2013 - BusinessWire
Merck Partners With TRUSTe to Become Certified Under APEC Cross Border Privacy Rules 9:00 a.m. Nov. 18, 2013 - Marketwire
Merck's New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review 8:30 a.m. Nov. 18, 2013 - BusinessWire
RedHill Biopharma Announces Positive Scientific Advice Meeting and European Marketing Application Strategy for RHB-103 (Migraine) 8:00 a.m. Nov. 18, 2013 - GlobeNewswire
Interim Data to Be Presented for MK-3475, Merck's Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma 5:00 p.m. Nov. 15, 2013 - BusinessWire
Akorn Acquires Three Branded Ophthalmic Products from Merck 9:00 a.m. Nov. 15, 2013 - BusinessWire
Merck Strengthens its Presence in China with New Pharmaceutical Manufacturing Facility 2:00 a.m. Nov. 15, 2013 - PR Newswire
Today's Research: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 6:21 p.m. Nov. 14, 2013 - PR Newswire
Healthcare Sector Announces Financial Results and Financial Restatements - Research Report on Merck, Health Management Associates, ZELTIQ, MAKO, and Amarin 8:00 a.m. Nov. 13, 2013 - PR Newswire
Merck Enters into Further Global Co-Development and Commercialization Agreement for PARP Inhibitor with Chinese R&D Company BeiGene 2:30 a.m. Nov. 13, 2013 - PR Newswire
InSite Vision Reports Third Quarter 2013 Financial Results 4:03 p.m. Nov. 12, 2013 - BusinessWire
Merck Animal Health HomeAgain® Announces Hero of the Year Award Winner 8:00 a.m. Nov. 12, 2013 - PR Newswire
Acquisition, Corporate News Analysis: Apple Inc, Bank of America, Intel Corporation, Merck & Co, Globalstar 9:15 a.m. Nov. 11, 2013 - PR Newswire
Clinical Study Results, Approvals, Financial Results, New Facilities, and Business Expansions - Research Report on Merck, UnitedHealth Group, NPS Pharmaceuticals, Abbott, and Medtronic 8:00 a.m. Nov. 11, 2013 - PR Newswire
Valuation
P/E Current
24.47
P/E Ratio (with extraordinary items)
31.97
P/E Ratio (without extraordinary items)
20.47
Price to Sales Ratio
2.63
Price to Book Ratio
2.34
Price to Cash Flow Ratio
12.57
Enterprise Value to EBITDA
8.29
Enterprise Value to Sales
3.25
Total Debt to Enterprise Value
0.16
Efficiency
Revenue/Employee
0.57
Income Per Employee
0.07
Receivables Turnover
5.89
Total Asset Turnover
0.45
Liquidity
Current Ratio
1.90
Quick Ratio
1.54
Cash Ratio
0.90
Profitability
Gross Margin
65.66
Operating Margin
22.16
Pretax Margin
18.46
Net Margin
13.02
Return on Assets
5.84
Return on Equity
11.47
Return on Total Capital
8.47
Return on Invested Capital
8.85
Capital Structure
Total Debt to Total Equity
38.79
Total Debt to Total Capital
27.95
Total Debt to Total Assets
19.38
Long-Term Debt to Equity
30.66
Long-Term Debt to Total Capital
22.09
Merck & Co. Inc. MRK Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 23.85B 27.43B 45.91B 48.13B 47.35B
Cost of Goods Sold (COGS) incl. D&A 5.46B 9.02B 18.4B 16.41B 16.26B
COGS excluding D&A 3.83B 6.44B 11.02B 8.98B 9.28B
Depreciation & Amortization Expense 1.63B 2.58B 7.38B 7.43B 6.98B
Depreciation 1.45B 1.65B 2.68B 2.33B 1.98B
Amortization of Intangibles 186.1M 921.8M 4.7B 5.1B 5B
Gross Income 18.39B 18.41B 27.52B 31.73B 31.09B
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 11.95B 14.27B 24.13B 21.34B 20.6B
Research & Development 4.68B 5.85B 10.99B 7.88B 7.91B
Other SG&A 7.28B 8.43B 13.14B 13.46B 12.69B
Other Operating Expense 0 0 0 0 0
Unusual Expense (778.6M) 1.83B 1.12B 2.6B 2.13B
EBIT after Unusual Expense 778.6M (1.83B) (1.12B) (2.6B) (2.13B)
Non Operating Income/Expense (226.7M) 11B (566M) (519M) 221M
Non-Operating Interest Income 631.4M 210.2M 83M 199M 232M
Equity in Affiliates (Pretax) 2.56B 2.24B 587M 610M 642M
Interest Expense 251.3M 458M 715M 749M 714M
Gross Interest Expense 251.3M 458M 715M 749M 714M
Interest Capitalized 0 0 0 0 -
Pretax Income 9.93B 15.29B 1.65B 7.33B 8.74B
Income Tax 2B 2.27B 671M 942M 2.44B
Income Tax - Current Domestic 1.18B (48M) 317M 911M 1.12B
Income Tax - Current Foreign 292.4M 495.4M 1.45B 1.57B 651M
Income Tax - Deferred Domestic 474.3M 2.26B 685M (854M) 992M
Income Tax - Deferred Foreign 55.8M (437.3M) (1.78B) (683M) (323M)
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 - (15M) (3M)
Consolidated Net Income 7.93B 13.02B 982M 6.38B 6.3B
Minority Interest Expense 123.9M 122.9M 121M 120M 131M
Net Income 7.81B 12.9B 861M 6.26B 6.17B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 7.81B 12.9B 861M 6.26B 6.17B
Preferred Dividends 0 2.1M 0 0 0
Net Income Available to Common 7.81B 12.9B 861M 6.26B 6.17B
EPS (Basic) 3.66 5.67 0.28 2.04 2.03
Basic Shares Outstanding 2.14B 2.27B 3.1B 3.07B 3.04B
EPS (Diluted) 3.64 5.65 0.28 2.02 2.00
Diluted Shares Outstanding 2.15B 2.27B 3.12B 3.09B 3.08B
EBITDA 8.07B 6.71B 10.77B 17.82B 17.47B
Merck & Co. Inc. MRK Filings
SEC Filings for Merck & Co. Inc.
Filing Date Document Date Type Category Amended
11/07/2013 09/30/2013 10-Q Quarterly Reports
10/28/2013 10/28/2013 8-K Special Events
10/01/2013 09/30/2013 8-K Special Events
08/07/2013 06/30/2013 10-Q Quarterly Reports
07/30/2013 07/30/2013 8-K Special Events
05/30/2013 05/28/2013 8-K Special Events
05/22/2013 05/20/2013 8-K Special Events
05/20/2013 05/20/2013 8-K Special Events
05/09/2013 03/31/2013 10-Q Quarterly Reports
05/01/2013 05/01/2013 8-K Special Events
04/15/2013 05/28/2013 DEF 14A Proxy Statement
03/07/2013 03/04/2013 8-K Special Events
02/28/2013 12/31/2012 10-K Annual Reports
02/19/2013 02/14/2013 8-K Special Events
02/13/2013 N/A SC 13G/A Institutional Ownership *
02/05/2013 N/A SC 13G/A Institutional Ownership *
02/01/2013 02/01/2013 8-K Special Events
11/29/2012 11/26/2012 8-K Special Events
11/09/2012 09/30/2012 10-Q Quarterly Reports
10/26/2012 10/26/2012 8-K Special Events
SEC Filings provided by EDGAR Online, Inc.
MRK Merck & Co. Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/MRK/quote
Stock Chart http://www.otcmarkets.com/stock/MRK/chart
Company Info http://www.otcmarkets.com/stock/MRK/company-info
Recent News http://www.otcmarkets.com/stock/MRK/news
Financials http://www.otcmarkets.com/stock/MRK/financials
Filings and Disclosure http://www.otcmarkets.com/stock/MRK/filings
Short Sales http://www.otcmarkets.com/stock/MRK/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/MRK/insider-transactions
Research Reports http://www.otcmarkets.com/stock/MRK/research
Summary http://finance.yahoo.com/q?s=MRK
Historical Prices http://finance.yahoo.com/q/hp?s=MRK+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=MRK
Basic Chart http://finance.yahoo.com/q/bc?s=MRK+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=MRK+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=MRK+Headlines
Press Releases http://finance.yahoo.com/q/p?s=MRK+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=MRK+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=MRK+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=MRK+Industry
Major Holders http://finance.yahoo.com/q/mh?s=MRK+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=MRK+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=MRK+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=MRK
Balance Sheet http://finance.yahoo.com/q/bs?s=MRK
Cash Flow http://finance.yahoo.com/q/cf?s=MRK+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/MRK
Market Watch http://www.marketwatch.com/investing/stock/MRK
Bloomberg http://www.bloomberg.com/quote/MRK:US
Morningstar http://quotes.morningstar.com/stock/s?t=MRK
Bussinessweek http://investing.businessweek.com/research/st...ticker=MRK
Barchart http://www.barchart.com/quotes/stocks/MRK
OTC Short Report http://otcshortreport.com/index.php?index=MRK
Investopedia http://www.investopedia.com/markets/stocks/MRK/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
